
3D Genomics Solves Cancer Case Where Sequencing Came Up Short: Anthony Schmitt, Arima Genomics
Mendelspod Podcast
00:00
Is This Just an Animal One Case Where I'm a Drugable Target?
We have a cohort of sarcomas that are negative for a driver mutation by DNA and RNA sequencing. We run them and we find some type of fusion event that implicates a gene that is the target of an FDA approved therapy or a diagnostic or prognostic marker 66% of the time. In brain tumors, it's about 40% in cole rectals,. Even though our numbers right now are relatively small around 15 patients. It's also in the 60s. And so overall, we've now looked at about 175 driver negative patients and in about a third of them, we find some kind of fusion involving the gene. That is the targetof an FDA approved Therapy today. Wow
Transcript
Play full episode